Summary of the Conference Call on Innovent Biologics and Eli Lilly Collaboration Company and Industry Involved - **Company**: Innovent Biologics (信达生物) - **Partner**: Eli Lilly (礼来制药) - **Industry**: Biopharmaceuticals, specifically focusing on oncology and immunotherapy Core Points and Arguments - **Strategic Collaboration Announcement**: On February 8, 2026, Innovent Biologics announced a strategic partnership with Eli Lilly to advance global research and development of innovative drugs in oncology and immunology [1][2] - **Seventh Collaboration**: This agreement marks the seventh collaboration between the two companies, further deepening their long-term and productive partnership aimed at delivering innovative therapies to global patients [1][2] - **New Collaboration Model**: The unique structure of this collaboration is designed to accelerate the global development process of Innovent's innovative R&D pipeline [1][2] Financial Aspects - **Initial Payment**: Innovent will receive an upfront payment of $350 million [3] - **Milestone Payments**: The company is eligible for up to approximately $8.5 billion in additional milestone payments related to R&D, regulatory, and commercialization achievements [3] - **Sales Revenue Sharing**: Innovent will have the right to receive a tiered sales share from net sales outside Greater China [4] Key Highlights of the Collaboration - **Complementary Strengths**: The collaboration aims to leverage the complementary strengths of both companies to accelerate the global R&D of innovative drugs [3][5] - **Innovent's Core Competencies**: Innovent's competitive edge lies in its mature antibody technology platform and efficient clinical development capabilities, which are emphasized as foundational for leading early-stage R&D [5] - **Antibody Technology Platform**: Innovent has a well-established platform for discovering fully human antibodies, supporting various formats such as monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), and fusion proteins [5] - **Clinical Development**: The company has a strong end-to-end capability from drug discovery to proof of concept (POC) in China, with 18 products approved for market [6] Pipeline and Clinical Experience - **Pipeline Scale**: Innovent has 18 products approved for market, with 4 molecules in Phase III/critical clinical trials and over 15 in clinical stages [6] - **Global Clinical Experience**: The company has extensive experience in conducting international multi-center research (MRCT) across various regions including the US, Australia, Japan, and Europe [6] - **Regulatory Progress**: Several pipeline products are expected to achieve breakthrough therapy designation (BTD) and initiate international Phase III trials by 2025 [6] Eli Lilly's Role - **Global Development and Commercialization**: Eli Lilly will be responsible for exclusive development, registration, commercialization, and manufacturing outside Greater China, utilizing its extensive global network to expedite product entry into major markets [7] - **Support for Innovent's Molecules**: Innovent's innovative molecules will benefit from Eli Lilly's international clinical platform for MRCT and rapid advancement in FDA/EMA registration processes [7]